Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

1.

Aspirin therapy is still underutilized among patients with type 2 diabetes.

Leitão CB, Krahe AL, Nabinger GB, Picon PX, Pecis M, Zaslavsky LM, Gross JL, Canani LH.

Arq Bras Endocrinol Metabol. 2006 Dec;50(6):1014-9.

PMID:
17221106
[PubMed - indexed for MEDLINE]
Free Article
2.

Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.

Bruno A, Grassi G, Dani F, Degiovanni M, Maghenzani G, Pagano G.

Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):42-6.

PMID:
15871850
[PubMed - indexed for MEDLINE]
3.

The benefit of aspirin therapy in type 2 diabetes: what is the evidence?

Sirois C, Poirier P, Moisan J, Grégoire JP.

Int J Cardiol. 2008 Sep 26;129(2):172-9. doi: 10.1016/j.ijcard.2008.01.030. Epub 2008 May 20. Review.

PMID:
18495263
[PubMed - indexed for MEDLINE]
4.

[Finding the right platelet anti-aggregant prescription for type-2 diabetes patients, according to the ADA 2003 criteria].

Raméntol Teys S, Pujol Blaya V, León de la Fuente M, León-Sanromà M.

Aten Primaria. 2006 Oct 31;38(7):413. Spanish. No abstract available.

PMID:
17173819
[PubMed - indexed for MEDLINE]
5.

[Primary prevention with aspirin for cardiovascular diseases in diabetic patients. What evidence supports the criteria of the ADA?].

Maciá Bobes C, Ronzón Fernández A, Fernández García E.

Aten Primaria. 2007 Mar;39(3):163-4. Spanish. No abstract available.

PMID:
17386212
[PubMed - indexed for MEDLINE]
6.

Does aspirin use reduce cardiovascular risk in diabetes?

Colwell JA.

Nat Rev Endocrinol. 2009 Apr;5(4):188-90. doi: 10.1038/nrendo.2009.44.

PMID:
19352314
[PubMed - indexed for MEDLINE]
7.

[Aspirin for the primary prevention of cardiovascular diseases in diabetic patients. A review of currently available tests].

Maciá Bobes C, Ronzón Fernández A, Fernández García E.

Rev Esp Salud Publica. 2006 Nov-Dec;80(6):613-20. Review. Spanish.

PMID:
17147301
[PubMed - indexed for MEDLINE]
9.

Decisional attributes of patients with diabetes: the aspirin choice.

Montori VM, Bryant SC, O'Connor AM, Jorgensen NW, Walsh EE, Smith SA.

Diabetes Care. 2003 Oct;26(10):2804-9.

PMID:
14514583
[PubMed - indexed for MEDLINE]
10.

Changing aspirin use in patients with Type 2 diabetes in the UKPDS.

Cull CA, Neil HA, Holman RR.

Diabet Med. 2004 Dec;21(12):1368-71.

PMID:
15569143
[PubMed - indexed for MEDLINE]
11.

Aspirin for primary prevention in patients with diabetes mellitus.

Nguyen KX, Marinac JS, Sun C.

Fam Med. 2005 Feb;37(2):112-7.

PMID:
15690251
[PubMed - indexed for MEDLINE]
Free Article
12.

[Use of aspirin in diabetic patients].

Türkoğlu S, Abaci A.

Anadolu Kardiyol Derg. 2007 Dec;7 Suppl 2:5-8. Review. Turkish.

PMID:
18160360
[PubMed - indexed for MEDLINE]
Free Article
13.
14.

Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.

Ferdinand KC.

J Cardiometab Syndr. 2006 Spring;1(2):133-40. Review.

PMID:
17679832
[PubMed - indexed for MEDLINE]
15.

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.

Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS; American Diabetes Association; American Heart Association; American College of Cardiology Foundation.

Diabetes Care. 2010 Jun;33(6):1395-402. doi: 10.2337/dc10-0555. No abstract available. Erratum in: Diabetes Care. 2010 Sep;33(9):2129-31. Diabetes Care. 2011 Jan;34(1):247-8.

PMID:
20508233
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.

Lafeber M, Grobbee DE, Spiering W, van der Graaf Y, Bots ML, Visseren FL; SMART Study Group.

Eur J Prev Cardiol. 2013 Oct;20(5):771-8. doi: 10.1177/2047487312449587. Epub 2012 May 30.

PMID:
22649123
[PubMed - indexed for MEDLINE]
17.

AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions.

Nicolucci A, De Berardis G, Sacco M, Tognoni G.

Eur Heart J. 2007 Aug;28(16):1925-7. Epub 2007 Jun 29.

PMID:
17604291
[PubMed - indexed for MEDLINE]
Free Article
18.

[Should we treat all diabetic patients with aspirin in primary prevention?].

Righetti A, De Moerloose P, Philippe J.

Rev Med Suisse. 2005 Jun 1;1(22):1500-4. Review. French.

PMID:
16025889
[PubMed - indexed for MEDLINE]
19.

Aspirin in the treatment of type 2 diabetes.

Kajubi SK.

Arch Intern Med. 2000 Feb 14;160(3):394. No abstract available.

PMID:
10668844
[PubMed - indexed for MEDLINE]
20.

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.

Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS.

Circulation. 2010 Jun 22;121(24):2694-701. doi: 10.1161/CIR.0b013e3181e3b133. Epub 2010 May 27. No abstract available.

PMID:
20508178
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk